Pay in 4 interest-free payments of $5.51 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
While Eli Lilly and Novo Nordisk benefit from pricing power and the financial resources to push innovation further, they also have the potential to face regulatory scrutiny and patent challenges
10.1016/S0025-7125(05)70587-3 150
The findings show remarkable growth in rigor, scope, and collaborationbut also reveal persistent gaps that must be addressed if evidence-based addiction treatments are to reach everyone who needs them
Mol Metab 3:241251
Single-research compound for receptor pathway studies
US$ 23.98
US$ 26.78
US$ 20.01
US$ 27.70
US$ 22.41
US$ 29.73
